



Ashdin Publishing
International Journal of Medical Biology
Vol. 1 (2014), Article ID 235870, 7 pages
doi:10.4303/ijmb/235870

Research Article

Zoledronic Acid and Leuprorelin Acetate, Alone or in Combination, Similarly Reduce Proliferation and Migration of Prostate Cancer Cells In Vitro

Barbara Mognetti,¹ Giuseppe La Montagna,¹ Maria Giulia Perrelli,^{1,3} Silvia Marino,¹ Pasquale Pagliaro,^{1,3} Cecilia M. Cracco,² and Claudia Penna^{1,3}

¹Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino, Regione Gonzole 10, Orbassano, 10043 Torino, Italy

²S.C. Urologia, Ospedale Cottolengo di Torino, Via San Giuseppe Benedetto Cottolengo 9, 10152 Torino, Italy

³Istituto Nazionale per le Ricerche Cardiovascolari (INRC), Via Irnerio 48, 40126 Bologna, Italy

Address correspondence to Barbara Mognetti, barbara.mognetti@unito.it

Received 12 May 2014; Revised 18 June 2014; Accepted 7 July 2014

Copyright © 2014 Barbara Mognetti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract We studied the effects of zoledronic acid (ZA) and leuprorelin acetate (LA) separately and combined on a human cell line derived from a bone metastasis of prostatic adenocarcinoma (PC3). In particular, we focused on the effects that drugs given singularly or in association may play on tumor evolution and metastatization. Cell proliferation, 2D- and 3D-migration were studied in basal conditions and under attractive stimuli exerted by bone marrow mesenchymal stem cells (BM-MSC). Either drug decreased PC3 proliferation, though ZA was much more cytotoxic than LA. However, LA cytotoxic concentrations are higher than those usually reached in vivo. Subtoxic concentration of either drug inhibited migration especially under BM-MSC medium stimuli via an Akt-dependent mechanism. The capability of either drug to inhibit cellular migration is in line with their well-known effect in limiting metastatization. Intriguingly, no additive effect on the antiproliferative activity or in hindering migration is observed when the drugs are administered concomitantly, compared to the effects of each drug alone.

Keywords gonadotropin-releasing hormone analogue; bisphosphonate; prostate cancer; cytotoxicity; metastatization

1. Introduction

GnRH receptors are present both in prostatic malignant tissue and carcinoma derived cell lines, suggesting that GnRH analogues such as leuprorelin acetate (LA) [28], normally used to treat advanced prostate cancer (PCa), can exert a local action [10]. An inhibition of proliferative activity in presence of GnRH agonists has been found in androgen independent and androgen dependent prostatic cancer derived cell lines [23] and in epithelial cells isolated from prostatic tumors [2].

Moreover, LA antagonizes the metastatic behavior of both androgen-independent cell lines, DU145 and PC3, by decreasing their capacity to invade a reconstituted matrix and to migrate in response to haptotactic stimuli [5]. Bone is the preferential site for PCa metastases. Bone metastases likely depend on crosstalk between metastatic cells, bone

matrix, osteoblasts and osteoclasts, and cellular components of the bone marrow microenvironment. Among these, bone marrow mesenchymal stem cells (BM-MSCs) play a paramount role in the so-called metastatic niche [14,22]. In particular, BM-MSC paracrine factors may allow tumor cells to access cellular niches favoring tumor cell survival and growth [14,22].

Administration of IV bisphosphonates, such as zoledronic acid (ZA), can prevent bone loss and modulate tumor cell migration and invasion [11] in breast and prostate cancer bone metastases in patients treated with GnRH agonists [20].

The beneficial effects of bisphosphonates in PCa patients are attributed to their inhibitory activity on osteoclast-mediated bone resorption, which is markedly increased in lytic and in blastic metastatic bone disease [9]. They likely act on two essential stages of metastatic process: (1) tumor cell adhesion to bone extracellular matrices and (2) invasion through extracellular matrix, via modulation of cell adhesion molecules and extracellular matrix interacting molecules [4].

In addition to their antiosteoclast effects, bisphosphonates directly inhibit in vitro the growth of breast [6], pancreas [30], and prostate cancer cells, in a concentration- and time-dependent manner [17].

Despite the absence, to our knowledge, of in vitro and achieved preclinical studies investigating any potential interaction in the coadministration of GnRH analogues and bisphosphonates, this association is considered the gold standard of metastatic PCa therapy. Particularly, pharmacodynamic drug interactions could be the result of overlapping mechanisms of action. Therefore, we wondered whether

drug interactions can positively or negatively modify both drug effect and/or toxicity. A better understanding of these potential interplays could be used to increase the therapeutic effect of a combination regimen or to minimize its toxicity. We, therefore, examined the antiproliferative and antimigratory effect of a GnRH analogue, LA, and of a bisphosphonate, ZA, alone or in combination, on PC3 cells in vitro, in basal and stimulated conditions, obtained by exposing PC3 cells to the medium conditioned by BM-MSCs. Moreover, we analyzed the role of these two drugs on Akt phosphorylation, which is one of the most notable mechanisms involved in cell proliferation and migration [16]. PC3 cells, isolated from bone metastases of PCa, were chosen because they mimic the castration-resistant phase of PCa patients treated with both GnRH analogues and bisphosphonates [15] and because they are thoroughly recognized as a representative of a highly metastatic PCa cell line, on account of, among other aspects, their lack of AC-tubulin [29] and increased levels of $\beta 1$ integrins and integrin-induced autophosphorylation of FAK [18]. PC3 cells are frequently used to study PCa bone metastasis both in vivo and in vitro [12, 13].

With this in vitro study, besides confirming the direct cytostatic effect of either drugs (ZA or LA), we also show, for the first time, that both drugs limit cell migration induced by BM-MSCs and that there is no additive effect when these drugs are used concomitantly. Therefore, we suggest that it is worthwhile to consider a therapeutic regimen in which the two classes of drugs are included in early stages when there are not yet signs of bone metastases in patients with PCa.

2. Materials and methods

All reagents were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated. Tissue culture plasticware was from Falcon (Franklin Lakes, NJ, USA). Zoledronic acid [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) was generously provided by Novartis (Surrey, UK) and leuprorelin acetate

(N-[1-[[1-[[1-[[1-[[1-[[5-(diaminomethylideneamino)-1-[2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxo-pentan-2-yl]carbamoyl]-3-methyl-butyl]carbamoyl]-3-methyl-butyl]carbamoyl]-2-(4-hydroxyphenyl)ethyl]carbamoyl]-2-hydroxy-ethyl]carbamoyl]-2-(1H-indol-3-yl)ethyl]carbamoyl]-2-(3H-imidazol-4-yl)ethyl]-5-oxo-pyrrolidine-2-carboxamide).

was from Takeda (Osaka, Japan)

2.1. Cell culture

PC3 cells (human androgen-independent cells derived from a bone metastasis of prostatic adenocarcinoma) were purchased from ATCC (Rockville, MD, USA).

Cells were maintained at 37 °C in a humidified 5% CO₂ atmosphere in RPMI 1640 containing 10 mL/L penicillin and streptomycin solution, NaHCO₃ 2 g/L (7.5% w/v), 10% Fetal Bovine Serum (FBS) decomplemented for 30 min at 55 °C.

2.2. Bone marrow mesenchymal stem cells (BM-MSC) isolation and production of BM-MSC conditioned medium

Bone marrow cells were harvested from femurs of adult rats as detailed in the work of Raimondo et al. [25]. Animals received care in accordance with the Italian law (DL-116, 27 January 1992), which complies with the Guide for the Care and Use of Laboratory Animals by the US National Research Council.

We previously demonstrated that BM-MSCs isolated with this procedure are CD90⁺ and CD34/CD45⁻ and that under opportune stimuli they can differentiate [7,25]. We also previously reported that BM-MSCs stimulate PCa cell migration [22]. BM-MSCs were therefore included in the present study according to the described protocols.

BM-MSC conditioned medium was collected after three days of culture, centrifuged to eliminate cells and cellular debris, and freshly used or frozen [22].

2.3. Proliferation assay

PC3 cells were seeded into flat-bottomed 96-well microplates (1,000/100 μ L culture medium/well) and allowed to attach overnight in complete medium before drugs addition. Drugs were added to culture medium, alone or in combination, testing various concentrations from 2.5 μ M to 50 μ M (ZA) [19] and 0.5 μ M to 100 μ M (LA) [23] for 24–96 h, according to protocols.

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed as described by Mognetti et al. [21]. Data (mean \pm standard errors) were the average values of 8 replicates. Each experiment was repeated thrice. Cell viability was expressed as percentage of living cells with respect to controls.

2.4. 2D migration assay-wound healing

PC3 cells were seeded in a 6-well plate at 30,000 cells/well. When confluent, we performed a cross “wound” in each well with a p1000 tip [8], then wells were washed thrice with PBS and medium replaced without (control) or with single (ZA 5 μ M and LA 100 μ M) or combined drugs (ZA 5 μ M plus LA 100 μ M).

We photographed “wounds” on time-laps every 45 min to highlight migration until a maximum of 6 h and, as a final time point, at 24 h.

Experiments were repeated three times and every time five different points for each experimental condition were considered.




Figure 1: Proliferation assay. Effect of ZA (a) and LA (b) on PC3 proliferative activity. Arrows show IC50. * = $P < .05$ versus control conditions.

Images were analyzed using ImageJ software: migration was evaluated considering the reduction of wound area, and then compared to controls.

2.5. 3D migration assay

The transwell migration assay was used to measure the three-dimensional movements of cells. Migration assays were performed in transwells (BD Falcon cell culture inserts incorporating polyethylene terephthalate (PET) membranes with $8.0 \mu\text{M}$ pores, 1×10^5 pores/cm²).

When assessing spontaneous migration, culture medium was RPMI. When assessing migration in stimulated conditions, control medium was α MEM. When tests were performed in the presence of Wortmannine, cells were preincubated for 30 min at 37 °C with 100 nM.

Cells (10^5) resuspended in 200 μL of culture medium containing 2% FBS were seeded in the upper chamber of a transwell. The lower chamber (a 12-well plate) was filled with fresh or conditioned culture medium containing 2% FBS and placed in the incubator. After 6 h, cells were treated as detailed by Gambarotta et al. [8]. Wells were photographed using a BRESSER MikroCam 3 Mpx camera, with an optical microscope (Leica DC 100) at 100 \times . Five pictures were randomly chosen per well, and used to count the migrated cells with ImageJ software using cell-counter plug-in. Results from different experiments (performed at least three times in duplicate) were expressed as mean \pm SE.

In order to avoid any cytotoxic effect of potentially confounding migration results, we performed a cytotoxicity test as previously described at the same time and same conditions of every migration test.

2.6. Western blotting

Since Akt phosphorylation plays a role of paramount importance in cell migration [16], we tested the effects of ZA or LA on the phosphorylation levels of Akt (expressed as pAkt/Akt ratio) in the presence of studied drugs and in

the presence of Wortmannine (100 nM), used as a positive control.

Cells were seeded in 10 cm diameter Petri dishes, cultured until subconfluence, when drugs were added (ZA 5 μM and LA 100 μM). After 6 h incubation, cells were collected and treated as detailed by Mognetti et al. [22] and immunoblotted according to Penna et al. [24]. In parallel proliferation tests—as previously described—performed in the same culture conditions in order to exclude any confounding element, no significant cytotoxicity was appreciable at the chosen concentration after 6 h incubation.

Blots were probed with primary polyclonal antibody (Cell Signaling Technology, Danvers, MA, USA) suspended in TBS Tween 0.1%: anti-Akt (mouse, 1:800), anti-pAkt (Ser473, rabbit, 1:500), and anti-Vinculin (developed in rabbit, Sigma). Vinculin was used as an internal control.

HRP-conjugated anti-mouse (Amersham-GE Healthcare, Buckinghamshire, UK) and anti-rabbit (Santa Cruz Biotechnology) were diluted (1:6000 and 1:8000, resp.) in TBS Tween 0.025%. Bands were quantified using the ImageJ software.

Phosphorylation levels of Akt were expressed as ratio pAkt/Akt. All data were expressed as percentage modification relative to control conditions.

2.7. Statistics

Statistical analyses were performed by one-way or two-way ANOVA, and $P < .05$ was considered significant. If not differently specified, data are expressed as percentage mean \pm standard deviation compared to control.

3. Results

3.1. Inhibition of proliferative activity

ZA strongly inhibited cell proliferation (Figure 1(a)); cell growth was inhibited after 48 h already by 20 μM ZA, and even more strikingly after 72 h culture.




Figure 2: Proliferation assay. Effect of the simultaneous administration of LA (100 μM , constant concentration) plus ZA (2.5 to 40 μM , dotted line) on PC3 proliferation compared to cytotoxicity of 100 μM LA alone (triangle) and ZA alone (2.5 to 40 μM , black line). Results are expressed as percentage of control \pm SE.

Yet, no significant effect on cell proliferation was induced by LA at any concentration tested in the first 72 h (Figure 1(b)). A significant inhibition was induced by concentrations greater than 10 μM only after 96 h treatment (Figure 1(b)).

The simultaneous presence of the two drugs neither increased nor decreased the effect of the single drugs at any considered time point. An example is reported in Figure 2, where a constant amount of LA (100 μM , i.e., the highest concentration tested) was added to increasing concentrations of ZA. As in Figure 1, LA (100 μM) alone did not induce appreciable variation of cell proliferation (triangle in Figure 2).

To further analyze drug interactions, the concentrations of LA (from 1 μM to 100 μM) were increased in the presence of 5 μM ZA, and cells were grown for 72 h in the presence of the two drugs. Also in this case no significant variation of cell growth was observed after the addition of increasing concentrations of LA (data not shown).

3.2. Inhibition of migratory activity

Two-dimensional migration was inhibited both by ZA and LA, with significant effects already visible after 1.5 h (Figure 3). The simultaneous presence of the two drugs did not relevantly change the cell behavior, except between 2 and 3 h incubation, when it significantly quenched LA effects. On the other hand, no significant difference was evidenced between the drug combination and ZA alone, or between the two single drugs. The same trend is respected after 24 h incubation, when the three conditions are significantly different from control but not different between each other.

Since no difference in the rate of migration was evidenced when experiments were performed in RPMI or α MEM, we pooled data and globally referred to them as control.

Three-dimensional migration was significantly inhibited after 3 h (data not shown) and 6 h (Figure 4) by ZA and by LA, both in basal and in stimulated conditions. Again, the concurrent presence of the two drugs did not increase their inhibitory effect (even, it quenched LA effect).

In the same conditions, we measured Akt phosphorylation and revealed that both ZA and LA decrease it in basal and stimulated conditions.

Inhibition of Akt phosphorylation and that of 3D migration are not proportional (no direct correlation could be established), nevertheless the trend is clearly the same. Importantly, 3D migration rate was decreased by the inhibition of Akt phosphorylation (100 nM Wortmannine), both in basal and stimulated conditions.

4. Discussion

A major source of morbidity in patient with prostate cancer is the widespread bone metastases, which often grow in a castration-resistant manner and still are a major topic in the research for novel treatment strategies. Monotypic in vitro cultures are commonly employed to study drug effects on cell proliferation and migration. Cell lines are still the main experimental model used in many publications, despite the fact that animal models have become widely available in recent years. PC3 cells are androgen independent, proliferate normally in androgen deprived media in vitro and possess high migratory capability. In addition, PC3 xenograft




Figure 3: Two-dimensional migration. The wound healing was quantified every 45 min in time laps up to 6 h (a) and at 24 h (b), and is displayed as basal conditions (CTRL) or as the effect of 5 μ M ZA, 100 μ M LA or a combination of both drugs (5 μ M ZA + 100 μ M LA). Data are expressed as relative to control conditions \pm SE. Experiments were performed three times in duplicate. *P* values are reported in the underlying table; n.s. means difference being not statistically significant.




Figure 4: Three-dimensional cell migration and Akt phosphorylation. Effect of 5 μ M ZA, 100 μ M LA, the combination of both drugs (5 μ M ZA + 100 μ M LA) and 100 nM Wortmannine (W) on PC3 3D migration (black bars) and Akt phosphorylation (grey bars) in basal (CTRL) and stimulated (CM) conditions. Data are expressed as percentage towards basal conditions (CTRL). * = *P* < .05 versus control conditions. # = *P* < .05 versus conditioned medium (CM).

tumors proliferate rapidly and are quite invasive. For those reasons, PC3 cells are thoroughly recognized as an appropriate model for the study of the more aggressive forms of PCa.

The use of complementary assays, such as wound healing and transwell motility assays, is commonly used to assess *in vitro* metastatic potentials [31]. Moreover, our coculture system permits to study the drug effects on the migration of PCa cells in conditions that more resemble the *in vivo* tumor microenvironment, by providing the tumor cells with contextual signals. This model has already been validated [22] and proved to be reliable in reproducing the chemotactic effect exerted by BM-derived cells on PCa.

This *in vitro* study strongly supports that ZA has cytotoxic effects on a PCa cell line derived from a bone metastases, an effect that is much less evident for LA. Yet, either drug limits cell migration in a similar extent. Intriguingly, no relevant additive effects can be appreciated between the two drugs in affecting cell migration and proliferation. The lack of additive effects as well as the similar effects on Akt phosphorylation suggests that diminution of the effect of every single drug is highly unlikely *in vivo*.

A direct cytotoxicity of ZA has been already described [17], though never in combination with LA. In our hands, ZA toxicity was already significant after 48 h culture at 20 μ M, regardless of LA cotreatment. In a previous study [19], the toxicity of ZA was observed at lower concentrations probably because of different experimental conditions. It is of note that, *in vivo*, the effective local concentrations of bisphosphonates at sites of active bone resorption are much higher than serum levels and may reach up to 10^{-3} M in the resorption lacunae [27]. It is possible therefore to infer that in treated patients the close association of cancer cells with actively resorbing osteoclasts and the bone matrix will result in exposure of tumor cells to bisphosphonates concentrations sufficient to induce their apoptosis [17].

It is much more difficult, on the other hand, to expect, *in vivo*, a direct cytotoxicity attributable to LA, since concentrations needed, as defined by our study and by other groups [5,23], cannot be reached with therapeutical dosages.

When used at subtoxic concentration, both ZA and LA significantly inhibit 2D migration, already after 1.5 h. This property is even more striking when cells are exposed to a chemotactic stimulus. Intriguingly, this phenomenon is probably very close to what happens *in vivo*, where bone microenvironment strongly influences cancer cells motility [3,32].

Caraglia et al. [1] described a decrease in the activation of PI3K/Akt pathway following treatment with ZA, suggesting that it may act upstream of the metastasis, by inhibiting PCa cell migration towards metastatic sites through interference with this pathway mostly implicated in cell migration [16]. Our study concurs with that of Caraglia et al. by

suggesting that inhibition of migration provoked by ZA and LA might be mediated by inhibition of Akt phosphorylation, which, on the other hand, is increased when cells are exposed to a chemotactic stimulus fostering their motility.

We conclude that ZA is more cytotoxic than LA *in vitro*. However, due to the effective dosage of the two drugs, we suggest that such an effect is likely, *in vivo*, for ZA only. Nevertheless, both compounds strongly reduce basal and BM-MSC stimulated cell motility *in vitro*. Therefore, they are likely implicated in reduction of PCa cells motility, with great fall out on bone metastases formation. This anti-tumoral activity is in line with the recently demonstrated beneficial effects of these two compounds in PCa patients with bone metastases [26].

The clinical implications might be the possible increase in GnRH analogues dosage in castration-resistant patients, to increase its antiproliferative effect, and an early use of ZA before the appearance of the metastasis, with the aim of inhibiting PCa cell proliferation, promoting apoptosis and preventing cell migration.

Importantly, when these two drugs are used in association we do not observe unfavorable interactions between them on the studied parameters. However, we cannot rule out that association treatment regimen that enhances or inhibits the effect of the two drugs exists *in vivo*. The experience with this association has scarcely been studied *in vivo* under a pharmacological point of view; therefore studies such as ours are needed.

Conflict of interest The authors declare that they have no conflict of interest.

Acknowledgments This study was supported by Ricerca Sanitaria Finalizzata della Regione Piemonte (CMC), National Institutes of Cardiovascular Research (INRC-2010, to PP); Regione Piemonte (CP, PP), ex-60% (CP, PP), and PRIN-2008 (CP). The authors thank Novartis for kindly providing zoledronic acid. They also thank Dr. Francesca Bertolini for her assistance in manuscript editing.

References

- [1] M. Caraglia, M. Marra, C. Leonetti, G. Meo, A. M. D'Alessandro, A. Baldi, et al., *R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation*, *J Cell Physiol*, 211 (2007), 533–543.
- [2] E. Castellón, M. Clementi, C. Hitschfeld, C. Sánchez, D. Benítez, L. Sáenz, et al., *Effect of leuprolide and cetorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma*, *Cancer Invest*, 24 (2006), 261–268.
- [3] C. R. Cooper, C. H. Chay, J. D. Gendernalik, H. L. Lee, J. Bhatia, R. S. Taichman, et al., *Stromal factors involved in prostate carcinoma metastasis to bone*, *Cancer*, 97 (2003), 739–747.
- [4] P. G. Dedes, C. Gialeli, A. I. Tsonis, I. Kanakis, A. D. Theocharis, D. Kletsas, et al., *Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid*, *Biochim Biophys Acta*, 1820 (2012), 1926–1939.

- [5] D. Dondi, C. Festuccia, M. Piccolella, M. Bologna, and M. Motta, *GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system*, *Oncol Rep*, 15 (2006), 393–400.
- [6] O. Fromiguet, L. Lagneaux, and J. J. Body, *Bisphosphonates induce breast cancer cell death in vitro*, *J Bone Miner Res*, 15 (2000), 2211–2221.
- [7] M. P. Gallo, R. Ramella, G. Alloatti, C. Penna, P. Pagliaro, A. Marcantoni, et al., *Limited plasticity of mesenchymal stem cells cocultured with adult cardiomyocytes*, *J Cell Biochem*, 100 (2007), 86–99.
- [8] G. Gambarotta, D. Garzotto, E. Destro, B. Mautino, C. Giampietro, S. Cutrupi, et al., *ErbB4 expression in neural progenitor cells (st14a) is necessary to mediate neuregulin-1 β -induced migration*, *J Biol Chem*, 279 (2004), 48808–48816.
- [9] P. Garnero, N. Buchs, J. Zekri, R. Rizzoli, R. E. Coleman, and P. D. Delmas, *Markers of bone turnover for the management of patients with bone metastases from prostate cancer*, *Br J Cancer*, 82 (2000), 858–864.
- [10] V. J. Gnanapragasam, S. Darby, M. M. Khan, W. G. Lock, C. N. Robson, and H. Y. Leung, *Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumorigenic response to analogue therapy in hormone refractory prostate cancer*, *J Pathol*, 206 (2005), 205–213.
- [11] J. Green and P. Cl  zardin, *The molecular basis of bisphosphonate activity: A preclinical perspective*, *Semin Oncol*, 37 (2010), S3–S11.
- [12] Z. Hao, W. Fan, J. Hao, X. Wu, G. Q. Zeng, L. J. Zhang, et al., *Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo*, *Drug Deliv*, (2014).
- [13] J.-K. Jin, P.-C. Tien, C.-J. Cheng, J. H. Song, C. Huang, S.-H. Lin, et al., *Talin1 phosphorylation activates β 1 integrins: a novel mechanism to promote prostate cancer bone metastasis*, *Oncogene*, (2014).
- [14] J. Joseph, Y. Shiozawa, Y. Jung, J. K. Kim, E. Pedersen, A. Mishra, et al., *Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype*, *Mol Cancer Res*, 10 (2012), 282–292.
- [15] M. E. Kaighn, K. S. Narayan, Y. Ohnuki, J. F. Lechner, and L. W. Jones, *Establishment and characterization of a human prostatic carcinoma cell line (PC-3)*, *Invest Urol*, 17 (1979), 16–23.
- [16] D. Kim, S. Kim, H. Koh, S. O. Yoon, A. S. Chung, K. S. Cho, et al., *Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production*, *FASEB J*, 15 (2001), 1953–1962.
- [17] M. V. Lee, E. M. Fong, F. R. Singer, and R. S. Guenette, *Bisphosphonate treatment inhibits the growth of prostate cancer cells*, *Cancer Res*, 61 (2001), 2602–2608.
- [18] Y. C. Lee, J. K. Jin, C. J. Cheng, C. F. Huang, J. H. Song, M. Huang, et al., *Targeting constitutively activated β 1 integrins inhibits prostate cancer metastasis*, *Mol Cancer Res*, 11 (2013), 405–417.
- [19] J. Mani, S. Vallo, K. Barth, J. Makarevic, E. Juengel, G. Bartsch, et al., *Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro*, *Prostate Cancer Prostatic Dis*, 15 (2012), 250–255.
- [20] M. D. Michaelson, D. S. Kaufman, H. Lee, F. J. McGovern, P. W. Kantoff, M. A. Fallon, et al., *Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer*, *J Clin Oncol*, 25 (2007), 1038–1042.
- [21] B. Mognetti, A. Barberis, S. Marino, F. Di Carlo, V. Lysenko, O. Marty, et al., *Preferential killing of cancer cells using silicon carbide quantum dots*, *J Nanosci Nanotechnol*, 10 (2010), 7971–7975.
- [22] B. Mognetti, G. La Montagna, M. G. Perrelli, P. Pagliaro, and C. Penna, *Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1 α* , *J Cell Mol Med*, 17 (2013), 287–292.
- [23] M. Montagnani Marelli, R. M. Moretti, S. Mai, P. Procacci, and P. Limonta, *Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I*, *Int J Oncol*, 30 (2007), 261–271.
- [24] C. Penna, G. Alloatti, S. Cappello, D. Gattullo, G. Berta, B. Mognetti, et al., *Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation*, *Am J Physiol Heart Circ Physiol*, 288 (2005), H2512–H2520.
- [25] S. Raimondo, C. Penna, P. Pagliaro, and S. Geuna, *Morphological characterization of GFP stably transfected adult mesenchymal bone marrow stem cells*, *J Anat*, 208 (2006), 3–12.
- [26] F. Saad, D. M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, et al., *A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma*, *J Natl Cancer Inst*, 94 (2002), 1458–1468.
- [27] M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, D. D. Thompson, et al., *Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure*, *J Clin Invest*, 88 (1991), 2095–2105.
- [28] M. R. Smith, *Androgen deprivation therapy for prostate cancer: new concepts and concerns*, *Curr Opin Endocrinol Diabetes Obes*, 14 (2007), 247–254.
- [29] K. Soucek, A. Kamaid, A. D. Phung, L. Kubala, J. C. Bulinski, R. W. Harper, et al., *Normal and prostate cancer cells display distinct molecular profiles of α -tubulin posttranslational modifications*, *Prostate*, 66 (2006), 954–965.
- [30] P. Tassone, P. Tagliaferri, C. Viscomi, C. Palmieri, M. Caraglia, A. D’Alessandro, et al., *Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro*, *Br J Cancer*, 88 (2003), 1971–1978.
- [31] J. Tome-Garcia, D. Li, S. Ghazaryan, L. Shu, and L. Wu, *ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells*, *PLoS One*, 9 (2014), e99525.
- [32] T. L. Whiteside, *The tumor microenvironment and its role in promoting tumor growth*, *Oncogene*, 27 (2008), 5904–5912.